hline1.jpg (2302 bytes) PRESS ROOM hline1.jpg (2302 bytes)
Aurobindo receives first tentative approval for Stavudine Oral Solution from US FDA
Aurobindo's 6 ARV products in World Health Organization (WHO) Pre-qualification list
Aurobindo selected for Patent Appreciation Award by IDMA
Aurobindo's receives final approval of Mirtazapine Orally Disintegrating Tablets
Aurobinoo's product included in World Health Organization (WHO) Pre-qualification list
Aurobindo receives approval for Cephalexin Capsules by US FDA
Aurobindo receives approval for Amoxicillin Tablets & Capsules
Aurobindo receives tentative approval for Lamivudine Oral Solution from UD FDA
Aurobindo gets EDQM approval for Flucloxacillin Sodium
US FDA grants tentative approval for Aurobindo's Sertraline
US FDA grants approval for Aurobindo's zidovudine
Aurobindo receives tentative approval for zidovudine tablet
Aurobindo’s products included in World Health Organization (WHO) Pre-qualification list
Aurobindo’s scientist conferred award
Aurobindo posts revenue of Rs.2807 Million in Q1.
Aurobindo gets EDQM approval for Domperidone & Domperidone Maleate
Canadian authority approves Aurobindo’s facilities
Aurobindo Pharma gets US FDA nod for lamivudine and zidovudine combination tablets
Aurobindo receives - first generic approval of Efavirenz
Aurobindo announces approval of Stavudine tablets
Aurobindo records revenue of Rs.11592 Million. Record facility approvals, DMFs/ANDAs filings and significant R & D expenses weigh on Aurobindo's bottom line
Aurobindo receives second ANDA approval from US FDA for PEPFAR
Aurobindo receives the first ARV approval from US FDA
USFDA approval received for Unit VIII Facility
Aurobindo receives NABL approval for its Clinical Laboratory
Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3rd product approval from USFDA
Aurobindo in Forbes list
Best under a Billion - Asia's Rising Companies
Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.
Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2
First product approval from US FDA received
Foray into Regulated Market crosses first major milestone
Company scientists conferred awards
Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31st July 2004
Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit
Aurobindo net profit at Rs. 127 crs surges by 23%
UK MHRA (UK MCA) approval received for Unit 3
Subscription to preferential issue of equity shares
Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales
Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram
Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%
Preferential Issue of Equity Shares
Aurobindo net profit spurts by 52.75% in Q1
Aurobindo crosses the landmark Net Profit of Rs.100 crores
Aurobindo's demonstration of R&D leadership in cephalosporins
Aurobindo Pharma launches cefepime
Second quarter profit jumps  41.13%
Aurobindo implementing ERP package
First quarter profit jumps 34%
Aurobindo posts Net Profit of  Rs. 68.51 crores
Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board
Aurobindo Pharma wins award for the best bulk drug company
Shares allotted to Templeton
Brazilian GMP certification received for the speciality generic formulations unit
Aurobindo Pharma acquires equity in Ranit Pharma
Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma
Aurobindo Pharma launches Aztreonam for the first time in India  
Aurobindo Pharma & Citadel promote a joint venture  
Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget
Aurobindo launches Cefactam (Cefoperazone plus Salbactam)
4th generation Cephalosporin – Cefpirome launched
Impressive Q3 performance 
Aurobindo shareholders approve Rs.125 crore Private Placement
Templeton to pick up equity
Aurobindo Pharma Board approves Rs. 125 crore private placement
Aurobindo Pharma launches two more antiretroviral products for HIV treatment
Restructuring on track
Aurobindo introduces two more drugs for treatment of Aids
Imunus Aurobindo launches two new anti-aids drugs
Aurobindo Pharma slashes prices of anti-aids drugs
Restructuring of Facilities
Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 31st October, 2005
AUROBINDO Q2 REVENUE IMPROVES TO RS.3271 MILLION.
- GROWTH OF OVER 20%

 
Hyderabad, India_October 31, 2005: Aurobindo Pharma Limited has registered a total income of Rs.3271 Million (Rs.2719 million) for the quarter ended September 30, 2005.
The EBIDTA stands at Rs.290.9 million (Rs. 273.5 million) showing a growth of 6.4% for the quarter.
After absorbing higher depreciation and interest amounting to Rs.265.8 million, (Rs.224.2 million), the Company has achieved Profit after Tax of Rs.36.4 million (Rs.25.6 million) for the quarter.
The export sales during the quarter have increased from Rs.1250.4 million to Rs.1506.2 million.
The formulation sales has increased by 120% to Rs.367.9 million (Rs.166.9 million). Going forward, the formulation sales is expected to contribute higher for the growth of the Company in view of the regulatory approvals.
Aggressive filings in US and other regulated market continues:
Particulars

Q2

Cumulative as on 30.09.2005

Cumulative as on 30.09.2005
USA Other Markets USA Other Markets
DMF 6 5 41 59
ANDAs 8 18 35 77
It may be noted that, during the quarter, Zidovudine oral solution 50 mg/5 ml and Zidovudine tablets 300 mg had been given final approval by US FDA thus taking total approvals to 5 in US market. Further, Aurobindo also received tentative approval for Sertraline Hydrochloride tablets 25 mg (base), 50 mg (base) and 100 mg (base) for US market.
Aurobindo has filed additional 13 patents during the quarter and the cumulative filings stand at 152 as of September 2005.
During the quarter Aurobindo won “The best bulk drug company award” for the 3rd time given away by Express Pharma Pulse, a leading Pharma publication.
Aurobindo has really geared up in the ARV segment by clinching more approvals under the PEPFAR program. As of date, the company has received 7 approvals for the purpose of PEPFAR program. The products approved under PEPFAR program are Zidovudine tablets 300 mg, Lamivudine tablets 150 mg & 300 mg, Nevirapine tablets 200 mg, Lamivudine & Zidovudine combination tablets 150 mg/300 mg, Zidovudine oral solution 50 mg/5 ml, Efavirenz tablets 600 mg and Stavudine capsules 30 mg & 40 mg. The World Health Organization (WHO), Geneva, has also included Aurobindo’s products in its pre-qualification list. The Company has made a small beginning under PEPFAR program and it hopes to bag good orders under the program.

Top

________________________________________________________________